
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
8.21 (USD) • At close March 11, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Rocket Pharmaceuticals, Inc. |
Symbool | RCKT |
Munteenheid | USD |
Prijs | 8.21 |
Beurswaarde | 875,432,300 |
Dividendpercentage | 0% |
52-weken bereik | 8.06 - 28.73 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gaurav D. Shah M.D. |
Website | https://rocketpharma.com |
An error occurred while fetching data.
Over Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)